Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stabilizing insulin-like growth factor-I in poly(D,L-lactide-co-glycolide) microspheres.

L Meinel1, O E Illi, J Zapf

  • 1Department of Applied BioSciences, Galenical Pharmacy, ETH Zurich, Winterthurer Strasse 190, 8057 Zurich, Switzerland.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|February 13, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosing peri-implant disease using the tongue as a 24/7 detector.

Nature communications·2017
Same author

Altered glycosylation of complexed native IgG molecules is associated with disease activity of systemic lupus erythematosus.

Lupus·2014
Same author

Aspartyl phosphates in the regulatory control of bacterial response.

Amino acids·2013
Same author

Trophically and topographically functionalized silk fibroin nerve conduits for guided peripheral nerve regeneration.

Biomaterials·2009
Same author

Experimental arthritis: effect on growth parameters and total skeletal calcium.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society·2009
Same author

BMP-silk composite matrices heal critically sized femoral defects.

Bone·2007

This study developed poly(D,L-lactide-co-glycolide) microspheres for controlled delivery of insulin-like growth factor-I (IGF-I) to enhance bone healing. The system successfully released biologically active IGF-I for up to 13 days.

Area of Science:

  • Biomaterials Science
  • Drug Delivery Systems
  • Regenerative Medicine

Background:

  • Recombinant human insulin-like growth factor-I (IGF-I) is crucial for bone healing.
  • Controlled, localized delivery of IGF-I is needed to optimize therapeutic effects.
  • Poly(D,L-lactide-co-glycolide) (PLGA) is a suitable biomaterial for microencapsulation.

Purpose of the Study:

  • To develop a controlled drug delivery system for IGF-I using PLGA microspheres.
  • To ensure the stability and biological activity of IGF-I during microencapsulation and release.
  • To evaluate the sustained release profile of IGF-I from the developed microspheres for bone healing applications.

Main Methods:

  • IGF-I was microencapsulated into PLGA 50:50 using a W(1)/O/W(2) dispersion method.

Related Experiment Videos

  • Protein stability was assessed using High-Performance Liquid Chromatography (HPLC) and Radioimmunoassay (RIA).
  • In vitro release kinetics and biological activity (fat cell assay) of IGF-I from microspheres were evaluated.

    • Main Results:

    • Ultrasonication caused significant IGF-I degradation, but excipients (bovine serum albumin, succinylated gelatin, poly(ethyleneglycol)) protected the protein.
    • Co-encapsulation of excipients maintained IGF-I structural integrity and biological activity.
    • Microspheres provided sustained IGF-I release for up to 13 days with a pulsatile pattern, confirmed by biological activity assays.

    Conclusions:

    • Developed PLGA microspheres effectively deliver biologically intact IGF-I in a controlled manner.
    • The 13-day release profile is relevant for promoting bone fracture healing.
    • This system holds promise for localized IGF-I therapy in orthopedic applications.